

Identifying and developing next-generation therapies that significantly improve patients' lives

RTW Venture Fund Limited (the "Company" or LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with growth potential across the life sciences sector. Our approach is driven by applying deep scientific expertise with a long-term investment horizon. The Company is managed by RTW Investments, LP (the "Investment Manager"), a leading healthcare-focused entrepreneurial investment firm with a track record of supporting companies developing life-changing therapies.

Market view

- The small-cap heavy Russell 2000 Biotech Index finished -27% YE. This performance is most striking compared to the broader markets. The S&P500 finished +27%, making small-cap biotech's 54% underperformance the largest in history.
- Valuations for the Nasdaq Biotechnology Index (NBI) and SPDR S&P Biotech (XBI) have returned to the historical average. This continues to be coupled with historically low interest rates and historically high innovation.
- The FDA approved 60 new drugs, topping last year's 59. mRNA established itself as the preferred modality for Covid vaccines, and Intellia reported human proof-of-concept for in vivo CRISPR, unlocking another new modality in the battle against disease.
- Sector M&A deal volume of \$109B is down from \$169B in 2020 and is the 2nd lowest in the last 8 years. We speculate that the mix of more attractive valuations, growing pressure from the coming wave of patent expirations, and an explosion of Covid related cash will translate into M&A in 2022.
- We think the primary market risks that bear watching sit largely outside of healthcare and revolve around equities and the dynamic between inflation and rates.

Latest update

- In 2021, the main detractor to NAV was the Rocket share price (-22%), offset by performance of our private company JIXNG (+2.6%), other core positions (+1.5%), and IPOs of Immunocore (+1.3%), Prometheus (+4.1%), resulting in c.-12.8% NAV decrease.
- Rocket's share price declined 60% in 2021. FDA put its Danon program on clinical hold in May to ensure adequate safeguards for patients in its clinical study. The trial was allowed to resume in August. The company also shared an update from the first five Danon patients in November. While the data suggest four patients have been stable over 1-2 years on study, investors expressed concern that a lack of improvement in certain measurements may make Phase 3 trial design more challenging. Rocket remains among the top 3 largest independent gene therapy companies by market cap.
- It was a difficult year for gene therapy as a subsector. Of 30 publicly traded gene therapy companies, the median decline was 54%, with only 3 companies up on the year, no drug approvals, and no public acquisitions. Recent setbacks have spanned safety, efficacy, and CMC.
- We believe the companies best positioned to overcome these near-term challenges will be those who focus on therapies for severe diseases with limited options and that also have meaningful commercial potential.
- Rocket's talented team and programs have been committed to this mission from the start, and we remain optimistic for both our existing programs and new opportunities.

Highlights

64.4%

Ordinary NAV growth since inception

71.2%

Total shareholder return since inception

US\$363M

Ordinary NAV

US\$1.71

NAV per ordinary share


Performance overview

Performance through 31 December 2021 net of investment expenses, 1.25% management fee, and 20% annual performance allocation fee. Historical rates of return are not indicative of future results.


Performance (NAV % return)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
2021	3.0	3.2	-10.8	2.3	-2.6	3.0	-6.9	2.8	-2.3	1.8	-7.9	2.3	-12.8
2020	-3.9	-2.3	-15.1	7.4	12.1	9.4	1.6	3.6	-2.7	6.8	10.2	21.7	53.9
2019	-	-	-	-	-	-	-	-	-	-	11.5	9.9	22.5

RTW.L share price vs NAV per share



RTW.L vs Benchmarks



Fund information


Structure: Closed End Investment Fund
 Domicile: Guernsey
 Listing: London Stock Exchange
 Segment: Premium listing
 Financial Year End: 31 December
 SEDOL: BKTRRM2; BNNXW5
 ISIN: GG00BKTRRM22
 Ticker: RTW and RTWG

Investment Manager: RTW Investments, LP
 Administrator: Elysium / MSFS
 Custodian: Barclays, Goldman Sachs
 Registrar: Link Asset Managers
 Corporate Broker: JPMorgan Cazenove, Barclays
 Fees: 1.25%/20 over 8% hurdle with catchup
 Denomination: USD and Sterling


RTW Venture Fund portfolio

As of 31 December 2021, c. 2/3 of NAV is invested in core portfolio holdings, which are companies that were initially added to our portfolio as private investments. As we retain our private investments beyond IPO, our core portfolio consists of both privately-held and publicly-listed companies; c. 1/3 of NAV is invested in publicly listed non-core holdings, which mirror holdings in our private funds, to mitigate cash drag.


Portfolio breakdown (%)




Subsector exposure (%)



Stage of initial investment (%)



Portfolio exposure (%)



Portfolio highlights:

3

New portfolio companies added in Q4 2021

42

Portfolio companies Launched with 6 portfolio companies, added 36 since IPO

15

Portfolio companies IPOed between 2020 and 2021 With an average step-up to IPO of 1.9x and first-day IPO performance of +24%

RTW Venture Fund portfolio summary (core portfolio holdings >1.1% of NAV)

Portfolio company	Description	Public/Private*	Clinical stage	Expected upcoming catalyst	% NAV
rocket pharma	Gene therapy platform company for rare pediatric diseases. Five clinical programs for Fanconi anemia, Danon, LAD, PKD and IMO.	Public: "RCKT"	Phase 2	Q2 2022	13.3%
JIXING	NewCo focused on acquiring rights from innovative therapies in the West for development and commercialization in China.	Private	Phase 3	Series D; H1 2022	6.6%
Prometheus Biosciences	Precision medicine company focused on IBD, a chronic inflammatory disease of GI tract; lead antibody program against TL1A.	Public: "RXDX"	Phase 1	H1 2022	5.6%
AVIDITY BIOSCIENCES	Antibody conjugated RNA medicines company. Lead program for myotonic dystrophy, a degenerative disease with no therapy.	Public: "RNA"	Phase 1	H1 2022	4.3%
RTW Royalty #2	Royalty as a part of RTW-Urogen deal	Private	-	-	3.4%
IMMUNOCORE	T-cell receptor therapy company focused on oncology and infectious disease. Lead program for uveal melanoma.	Public: "IMCR"	Registrational	Q1 2022	2.9%
RTW Royalty #1	Royalty as a part of RTW-Ji Xing-Cytokinetcs deal	Private	-	-	2.6%
C4 Therapeutics	Targeted protein degradation company working on blood cancers.	Public: "CCCC"	Phase 1	H1 2022	2.5%
TENAYA THERAPEUTICS	Biotech developing therapies that can address the underlying cause of heart disease; lead asset gene therapy for HCM	Public**: "TNYA"	Preclinical	-	2.1%
GH Research	Clinical stage biotech developing therapies to manage mental disease	Public: "GHR"	Phase 2	-	1.8%
iTeos Therapeutics	Novel immune checkpoint clinical stage company, with lead programs targeting TIGIT and A2A in Phase ½ for advanced solid tumors	Public: "ITOS"	Phase 1 / 2	H1 2022	1.8%
LANDOS BIO PHARMA	Developer of oral therapies for autoimmune disease. Lead program for inflammatory bowel disease.	Public: "LABP"	Phase 2 / 3	Q2 2022	1.6%
tarsus	Clinical stage biotech developing first-in-class therapeutics for ophthalmic conditions.	Public: "TARS"	Phase 3	Q1 2022	1.3%
beta Bionics	Closed-loop pancreatic system for automated and autonomous delivery of insulin.	Private	Pivotal	-	1.3%
NKT	Biotech using a structure-based design to develop innovative small molecules against promising molecular targets in oncology	Private	Preclinical	-	1.2%
ventyx BIOSCIENCES	Clinical stage biotech advancing a promising immunology pipeline for autoimmune and inflammatory diseases	Public**: "VTYX"	Phase 2	-	1.2%
Encoded THERAPEUTICS	Gene therapy company developing treatments for rare pediatric CNS disorders	Private	Preclinical	-	1.1%
Aggregate of <1.1% core portfolio companies include: Milestone, Monte Rosa, Alcyone, Pyxis, Athira, Pulmonx, Biomea, Orchestra, Visus, Nuance, Numab, Ancora, Artiva, Yarrow, Prometheus Labs, Neurogastrx, Umoja, Artios, Magnolia, InBrace, Lycia, Cincor, Acelyrin and 2 companies pending announcement.					11.8%

*Based on 31 December 2021 valuation for private investments, ** subject to lock-up, illiquidity discount

THIS FACTSHEET IS NOT INTENDED TO OFFER OR TO PROMOTE THE OFFER OR TRANSFER OF THE SHARES (THE "SHARES") OF RTW VENTURE FUND LIMITED (THE "COMPANY") IN THE UNITED STATES OR TO ANY "U.S. PERSONS" ("U.S. PERSONS") AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT"). No part of this factsheet may be reproduced in any manner without the written permission of the Company. The possession or distribution of this factsheet in certain jurisdictions may be restricted by law and persons into whose possession this factsheet comes should inform themselves about and observe any applicable restrictions. This factsheet does not constitute or form a part of any offer to sell, or any solicitation of any offer to purchase or otherwise acquire, securities in any jurisdiction. The securities described in this factsheet may not be eligible for sale in certain jurisdictions or suitable for all types of investors. The Company has not been and will not be registered under the US Investment Company Act of 1940 (the "Investment Company Act") and the Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, transferred or delivered, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require the Company to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. This factsheet was prepared using the financial and other information available to the Company and RTW Investments, LP as at the date of this factsheet. The Shares are compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in EU Directive 2014/65/EU on markets and financial instruments, as amended (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, the Shares are traded on the Premium Segment of the London Stock Exchange, which is intended for institutional, professional, professionally advised, and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Premium Fund Segment. A key information document in respect of the Shares has been prepared by RTW Investments, LP and is available to investors at www.rtwfunds.com/venture-fund. This information in this document is believed to be accurate but has not been audited, reviewed or verified by any third party. This factsheet may describe past performance, which cannot be relied on as a guide to future performance. This factsheet may include statements regarding investment strategies, individual securities and economic and market conditions; however, there can be no guarantee that such statements will prove to be correct. This factsheet may include expressions of opinions that are speculative in nature and should not be relied on as statements of fact. This factsheet may include forward-looking statements which are subject to known and unknown risks and uncertainties that may cause actual results and events to differ materially from those expressed in or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by words like "will seek", "will target", "believe", "expect", "intend", or similar expressions. You should not place undue reliance on forward-looking statements. Each of the Company and RTW Investments, LP disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Neither the Company nor RTW Investments, LP accepts any liability for actions taken on the basis of the information provided in this factsheet. The information provided in this factsheet should not be considered a recommendation to buy, sell or hold any security.